On September 16, the government reduced to zero the import tax rate of several medical products, including the drug Atezolizumab for the treatment of cancer. The measure was adopted through the inclusion of this drug in the Brazilian List of Exceptions to the Common External Tariff (Letec).
The decision was promoted by the Executive Management Committee of the Foreign Trade Chamber (Camex) of the Ministry of Economy. Camex is the chamber responsible for formulating, adopting, implementing and coordinating policies and activities related to Brazilian foreign trade, attracting foreign direct investment, Brazilian investments abroad, tariff and non-tariff issues and export financing.
For its part, the Executive Management Committee (Gecex) is the executive collegiate nucleus of Camex, responsible for defining import and export rates, establishing trade defense measures and internalizing the rules of origin of trade agreements, among other attributions.